Talis Biomedical (TLIS) Revenue & Revenue Breakdown
Talis Biomedical Revenue Highlights
Latest Revenue (Y)
$412.00K
Main Segment (Y)
Grant
Main Geography (Y)
Product
Talis Biomedical Revenue by Period
Talis Biomedical Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $412.00K | -88.72% |
2022-12-31 | $3.65M | 100.00% |
2021-12-31 | - | -100.00% |
2020-12-31 | $10.94M | 175.03% |
2019-12-31 | $3.98M | 66.40% |
2018-12-31 | $2.39M | - |
Talis Biomedical Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | -100.00% |
2024-03-31 | $73.00K | -51.66% |
2023-12-31 | $151.00K | 98.68% |
2023-09-30 | $76.00K | 58.33% |
2023-06-30 | $48.00K | -64.96% |
2023-03-31 | $137.00K | 28.04% |
2022-12-31 | $107.00K | -85.34% |
2022-09-30 | $730.00K | 45.42% |
2022-06-30 | $502.00K | -78.30% |
2022-03-31 | $2.31M | -1061109.17% |
2021-12-31 | $-218.00 | -200.00% |
2021-09-30 | $218.00 | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $10.94K | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $1.51M | - |
Talis Biomedical Revenue Breakdown
Talis Biomedical Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 |
---|---|---|
Product | $412.00K | $3.65M |
Grant | $1.72M | $1.16M |
Quarterly Revenue by Product
Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|
Product | $73.00K | $227.00K | $48.00K | $137.00K | $107.00K | $730.00K | $502.00K | $2.31M |
Grant | - | $108.00K | $533.00K | $1.08M | $150.00K | $66.00K | $70.00K | $874.00K |
Talis Biomedical Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 22 |
---|---|
Grant | $1.16M |
Product | $3.65M |
Talis Biomedical Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BVS | Bioventus | $512.35M | $151.22M |
SGHT | Sight Sciences | $81.06M | $21.37M |
VAPO | Vapotherm | $68.67M | $16.88M |
NPCE | NeuroPace | $65.42M | $18.12M |
SSKN | STRATA Skin Sciences | $33.36M | $8.44M |
HSCS | Heart Test Laboratories | $18.60M | $14.70K |
NUWE | Nuwellis | $8.86M | $2.19M |
INVO | INVO Bioscience | $3.02M | $1.58M |
TNON | Tenon Medical | $2.93M | $719.00K |
TIVC | Tivic Health Systems | $1.18M | $140.00K |
TLIS | Talis Biomedical | $412.00K | - |
MOTS | Motus GI | $319.00K | $64.00K |
BJDX | Bluejay Diagnostics | - | - |
BBLG | Bone Biologics | - | - |
TLIS Revenue FAQ
What is Talis Biomedical’s yearly revenue?
Talis Biomedical's yearly revenue for 2023 was $412K, representing a decrease of -88.72% compared to 2022. The company's yearly revenue for 2022 was $3.65M, representing an increase of 100.00% compared to 2021. TLIS's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Talis Biomedical’s quarterly revenue?
Talis Biomedical's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $73K, a -51.66% decrease from the previous quarter (Q4 2023), and a -46.72% decrease year-over-year (Q1 2023). TLIS's quarterly revenue for Q4 2023 was $151K, a 98.68% increase from the previous quarter (Q3 2023), and a 41.12% increase year-over-year (Q4 2022).
What is Talis Biomedical’s revenue growth rate?
Talis Biomedical's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -89.64%.
What are Talis Biomedical’s revenue streams?
Talis Biomedical's revenue streams in c 23 are Product, and Grant. Product generated $412K in revenue, accounting 19.31% of the company's total revenue, down -88.72% year-over-year. Grant generated $1.72M in revenue, accounting 80.69% of the company's total revenue, up 48.45% year-over-year.
What is Talis Biomedical’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Talis Biomedical was Grant. This segment made a revenue of $1.72M, representing 80.69% of the company's total revenue.